Global Metabolic Disorder Therapeutics Market valuation to surpass USD 98 billion by 2027

July 21, 2021


According to the research report titled ‘Global Metabolic Disorder Therapeutics Market Size study, by Route of Administration (Oral, Parenteral and Others), by Disease (Diabetes, Lysosomal Disorders, Obesity and Others), by Therapy Type (Enzyme Replacement Therapy, Cellular Transplantation and Others), and Regional Forecasts 2021-2027’, available with Market Study Report LLC, global metabolic disorder therapeutics market was assessed at USD 60.16 billion in 2020 and is anticipated to accrue USD 98.52 billion by 2027, expanding at 7.3% CAGR between 2021-2027.
 

Surging incidences of obesity as well as diabetes, growing awareness about treatment methods, and technological developments are key factors spurring global metabolic disorder therapeutics market expansion.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/3930323/
 

As per the World Health Organization, 1.5 million people died worldwide of diabetes in 2019. Also, high blood glucose caused 2.2 million deaths in 2012. Likewise, according to the International Diabetes Federation, in 2019, 463 million adults (20-79 years) were living with diabetes worldwide. This number is projected to reach 700 million by 2045.
 

For the unaware, metabolic disorder is an illness which occurs when abnormal chemical reactions in the human body disrupt the process of converting digested food to energy.
 

The report cites that while growing awareness about importance of good metabolism and harmful effects of obesity will aid industry growth, high cost of therapies and shortage of unequivocal regulatory policies will act as challenge.
 

Based on route of administration, worldwide metabolic disorder therapeutics market is divided into parenteral, oral, and others. Speaking of disease type, the industry is bifurcated into diabetes, obesity, lysosomal disorders, and others. Moving on to therapy type, the business sphere is fragmented into enzyme replacement therapy, small molecule based therapy, cellular transplantation, substrate reduction therapy, drug therapy, and gene therapy.
 

Regionally speaking, North America held majority market share in the recent past owing to higher per capita income and expenditure on healthcare. Parallelly, Asia Pacific market is estimated to record rapid growth between 2021-2027, due to rising incidences of diabetes, obesity, and other metabolic disorders.
 

Key players profiled in the global metabolic disorder therapeutics industry report are Biocon Limited, Shire plc, Novo Nordisk A/S, Amgen Inc., Eli Lilly and Company, Actelion Pharmaceuticals Ltd., AbbVie Inc., Sanofi S.A., AstraZeneca plc, and Merck KGaA.

Chat with us